Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience.

چکیده

Teprotumumab is the only FDA-approved medication for thyroid eye disease (TED), showing benefits in reducing proptosis, diplopia, clinical activity score (CAS), and improving quality of life. This study describes the clinical outcomes of TED patients treated with Teprotumumab across 5 medical…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• بیماری چشمی تیروئید